Overview

Paricalcitol Injection Phase II Trial

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
0
Participant gender:
All
Summary
The PK and tolerability of paricalcitol after repeated intravenous administration for 2 weeks (total 6 doses at every HD session) are studied in subjects with 2°HPT who are receiving HD 3 times a week for stable chronic renal failure.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Abbott
Treatments:
Ergocalciferols
Criteria
Inclusion Criteria:

- Subjects with 2°HPT who are receiving HD 3 times a week for stable chronic renal
failure

Exclusion Criteria:

- Subject is considered by investigator, for any reason, to be an unsuitable candidate
for the study